HU-210

HU-210 is a synthetic classical cannabinoid developed as a highly potent analogue of THC. It is a stereochemically defined dibenzopyran and acts as a strong agonist at both CB₁ and CB₂ receptors. Its very high receptor affinity and long-lasting effects have made it a widely used research compound, although it has no established therapeutic use in humans.

Chemistry and history

HU-210 was first synthesised in Israel in 1988 by Raphael Mechoulam and colleagues. Its structure is closely related to THC, but it contains a modified side chain and a different stereochemical arrangement that produces much stronger receptor activity. It belongs to the classical cannabinoid group, unlike the indole- and indazole-based synthetic cannabinoids that appeared later in herbal smoking mixtures.

HU-210 has been identified in products sold as synthetic cannabis. UNODC describes it as a synthetic analogue of THC and notes that it has been reported in products sold in the United States and other countries (UNODC synthetic cannabinoid substance group).

Pharmacology

HU-210 is a high-efficacy agonist at CB₁ and CB₂ receptors. EUDA cites a CB₁ Ki value of approximately 0.06 nM, more than 100 times tighter binding than THC in the comparison used. Other reviews report subnanomolar affinity at both receptor subtypes, although exact values vary between assay systems (EUDA synthetic cannabinoid profile; Synthetic cannabinoids: epidemiology and pharmacodynamics, 2014).

Its stereochemistry is important: cannabinoid receptor activity is highly dependent on the three-dimensional arrangement of the molecule. HU-210 is the active stereoisomer, and its high potency has made it useful in experimental work on cannabinoid signalling.

Effects in experimental models

HU-210 produces strong cannabimimetic effects in animal models, including reduced locomotor activity, hypothermia, antinociception and catalepsy. It has been used to investigate CB₁-mediated effects in the central nervous system and CB₂-related immune and inflammatory pathways.

Its long duration of action is frequently noted in pharmacological reviews. However, animal findings and receptor affinity measurements cannot directly predict subjective effects or their duration in humans.

Human effects and toxicity

Formal human studies of HU-210 are scarce. It has appeared in synthetic cannabinoid products, but the forensic record does not establish a clear clinical syndrome specific to HU-210. Reports involving mixtures containing HU-210 are difficult to interpret because the identity and concentration of other active substances may be uncertain.

High CB₁ efficacy is a relevant toxicological concern, but potency alone does not determine clinical outcome. The EUDA notes that synthetic cannabinoid products can vary substantially in composition and concentration, making the risk of unexpected exposure difficult to assess.

Research limitations

HU-210 remains an important laboratory ligand rather than an established medicine. Its receptor pharmacology is well characterised compared with many newer synthetic cannabinoids, but human pharmacokinetics, acute toxic range, dependence potential and long-term safety have not been adequately established.

Related compounds

HU-210 is related to THC, CP-55,940 and other classical or non-classical cannabinoid research ligands. Its dibenzopyran structure distinguishes it from naphthoylindoles such as JWH-018.